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Abstract 
Background: Aluminum has known neurotoxicity and may impair short-term bone 
health. In a randomised trial we showed reduced neurodevelopmental scores in preterm 
infants previously exposed to aluminum from parenteral nutrition solutions.  Here, in the 
same cohort, we test the hypothesis that neonatal aluminum exposure also adversely 
affects long-term bone health, as indicated by reduced bone mass. 
Methods: Bone area (BA) and bone mineral content (BMC) of lumbar spine, hip and 
whole body were measured with Dual X-ray Absorptiometry (DXA) in 13-15yr olds who 
were born preterm and randomly assigned standard or aluminum-depleted parenteral 
nutrition (PN) solutions during the neonatal period.  
Results: 59 subjects (32% of survivors) were followed. Those randomised to standard PN 
solution had lower lumbar spine BMC; apparently explained by a concomitant decrease 
in bone size. In non-randomised analyses, subjects exposed to neonatal aluminum intakes 
above the median (55mcg/kg) had lower hip BMC (by 7.6% (95% CI 0.21 to 2.38; 
p=0.02)), independent of bone (or body) size. 
Conclusion: Neonates exposed to parenteral aluminum may have reduced lumbar spine 
and hip bone mass during adolescence, potential risk factors for later osteoporosis and hip 
fracture.  These findings need confirmation in larger, more detailed studies. Nevertheless, 
given our previous finding of adverse developmental outcome in these subjects, and the 
sizeable number of contemporary infants undergoing intensive neonatal care who are still 
exposed to aluminum via parenteral feeding solutions, the potential adverse long term 
consequences of early aluminum exposure now deserve renewed attention. 
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Aluminum is the most common metallic element in the earth’s crust, but has no known 
biological role. It accumulates in the body when protective gastrointestinal mechanisms 
are bypassed, renal function is impaired, or exposure is high – all of which apply 
frequently to sick or preterm infants. Recognised clinical manifestations of aluminum 
toxicity, for instance from older renal dialysis solutions, included progressive dementia, 
anaemia and bone disease.  
 
Parenteral feeding solutions used in infants are contaminated with aluminum2,3, mostly 
from calcium gluconate solutions stored in glass vials, where complex-forming anions 
dissolve aluminum from the glass during autoclaving. When fed parenterally, infants 
retain up to 78% of the aluminum4, with high serum, urine and tissue levels1.  Increased 
aluminum concentrations have been observed post mortem in the brain of a parentally fed 
preterm infant5.   
 
Given the known toxicity of aluminum and the increasing survival of high risk neonates 
requiring parenteral nutrition, we elected to explore whether early exposure to 
intravenous aluminum has adverse long-term effects on health.  Assigning infants to high 
levels of aluminum exposure would have been unethical  However, because standard 
parenteral nutrition solutions contain significant aluminum, it was ethical for us to 
conduct a randomised trial comparing these with corresponding solutions specially 
sourced for low aluminum content.  Our trial, conducted in preterm infants, showed those 
exposed for >10 days to standard solutions had impaired neurologic development at 18 
months post-term6.  Bone health was not assessed at that stage. However, in rats, pigs, 
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dogs and adult humans excess aluminum accumulates at the mineralization front and is 
associated with reduced bone formation7.  Uraemic adults, and those on TPN have low 
bone formation, with patchy osteomalacia7. Sedman8 found bone aluminum 
concentrations were 10 times higher in preterm infants fed parenterally for more than 3 
weeks than in controls. None of these studies tested whether early aluminum exposure 
might influence long-term bone health; and, notably, result in reduced bone mass, 
believed to be a key predictor of osteoporosis and fracture risk.  In this study, therefore, 
we have used our trial to test experimentally the hypothesis that neonatal exposure to 
aluminum in standard parenteral nutrition solutions results in reduced bone mass during 
adolescence.   
 
Methods 
Study subjects were adolescents previously randomised to aluminum-depleted versus 
standard parenteral nutrition (PN) solutions during the neonatal period. Details are given 
elsewhere6 but summarised below.  
 
Randomised trial 
227 preterm infants (gestation < 34 weeks, birthweight < 1850g) were recruited from 
neonatal intensive care units in Cambridge and Norwich, UK. Infants were eligible for 
the study if there was a clinical decision to initiate intravenous feeding. Infants were 
randomly assigned according to a multiple random permuted-block method to receive 
either standard (S) aluminum-depleted (AD) PN solution. Investigators and staff were 
blind to the assignments. The study was approved by the research ethics committee, and 
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parental consent obtained. PN was introduced (typically on postnatal day 2 or 3) and 
stopped at the discretion of NICU medical staff. The composition of the two solutions 
(Table 1) was identical except that the AD solution contained less aluminum and more 
chloride, reflecting use of calcium chloride rather than calcium gluconate. Employing a 
mixed sodium-potassium phosphate solution instead of potassium acid phosphate further 
reduced aluminium and minimised the increase in chloride. 
 
Data were collected on the neonatal course of each infant, including detailed records of 
intravenous fluids and PN, enteral feeds and clinical events. The aluminum content of the 
parenteral solutions was measured by graphite-furnace atomic-absorption spectrometry 
(see Bishop6 for details). Total aluminum exposure from PN nutrition, expressed as 
mcg/kg, was calculated for each infant from the daily volume of each parenteral fluid.  
 
Follow-up study 
Subjects were invited for follow-up at age 13-15 years, to examine long-term effects of 
the intervention on (i) bone health; and (ii) cognitive and neurological outcomes (to be 
reported separately).  Children with neurological impairment or a previous Bailey score 
of <85 were excluded. The study was approved by the Great Ormond Street Hospital 
Research Ethics Committee. Subjects visited our research centre with a parent. Written 
informed consent was obtained from a parent and written assent from the subject. Weight 
was measured using digital scales and height using a portable stadiometer.  A food 
frequency questionnaire quantified current calcium intake (Calquest9); a simple 
questionnaire determined hours of weight-bearing activity/week; and parents rated the 
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child's activity level compared to his peers (rated 1-5: 1 = much less active; 5 = much 
more active). A general medical history and fracture history were taken. 
 
Bone densitometry 
Dual X-ray absorptiometry (DXA; Lunar Prodigy, GE, USA) was used to measure Bone 
Mineral Content (BMC), Bone Area (BA) and Bone Mineral Density (BMD) at the 
lumbar spine (L2-4), hips and whole body. Subjects wore light indoor clothing after 
removing metal objects. Total radiation exposure was below daily background levels 
(approx 7 microSv/day in the UK). As recommended by the International Society for 
Clinical Densitometry10 we used 'total body less head' values for whole body scans. 
 
Statistics 
Groups were compared using t-test or chi-square test. Some variables were transformed 
to ensure normal distribution.  The target sample size of 64 per group at follow-up would 
allow a difference of 0.5SD to be detected at 80% power and 5% significance.  
 
Bone mass was adjusted for size in three ways: (i) Bone Mineral Apparent Density 
(BMAD) of the lumbar spine, calculated as BMC/BA1.5 BMAD  Z scores were calculated 
for age, sex and ethnic group using UK machine-specific reference data11; (ii) for whole 
body bone mass, a two-stage procedure was used. The indices lean/height3 and 
BMC/lean0.7 were calculated with the power relationships required to remove any 
residual association with height determined using log-log regression; (iii) multiple 
regression was used firstly to examine the effect of PN solution assignment on later bone 
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mass at skeletal sites after adjusting for age, sex, pubertal stage and body size (weight and 
height); and secondly, to adjust for potential confounding factors, including current 
physical activity and calcium intake.  Continuous variables were transformed to natural 
logarithms for regression analyses, allowing coefficients to be expressed as percentages 
(sympercents12). 
 
Relationships between neonatal aluminum exposure and later bone mass were also 
examined in a non-randomised manner, using total neonatal aluminum exposure from 
TPN as both a continuous and dichotomous variable. Multiple regression was used with 
backward elimination of non-significant variables (p>0.05), adjusting for potential 
confounders including PN duration and factors related to neonatal illness severity.  
 
Results 
Comparison of randomised groups 
59 subjects from the original cohort (26% of those randomised; 32% of survivors; 33% of 
those eligible for follow-up) completed the bone health protocol (Figure 1). Subjects 
followed had significantly higher birth-weight SD score than those not seen, but there 
were no other baseline differences (Table 2). 
 
Neonatal data for those followed-up (Table 3) showed the randomised groups were well-
matched for birth-weight, gestation, days in the trial and days of iv feeding. There were 
no differences in neonatal peak plasma calcium, minimum phosphate or maximum 
alkaline phosphatase (ALP) (data not shown). Median (25th,75th centile) peak ALP 
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concentrations were 609 (502,751) and 606 (438,705) IU/l in groups AD and S 
respectively with maximum values of 982 and 1087IU/l.   Total neonatal aluminum 
exposure from PN expressed in mcg/kg was, by design, significantly higher in subjects 
who received standard feeding solutions. The proportion of human milk in the diet did 
not differ between groups. All infants required ventilatory support; with no group 
differences in duration or time spent in 30% oxygen. Socio-economic and educational  
indices did not differ between groups. 
 
At follow-up, there were no group differences in gender distribution, pubertal stages, age 
or anthropometric variables, although there was a trend towards greater weight, weight 
SDS and BMI in AD subjects (Table 4). Seven group S and 6 group AD subjects reported 
a current or previous history of asthma. Two group S and 5 group AD subjects were 
currently receiving no treatment, 5 group S and 1 group AD subjects were using 
bronchodilators, and one group S subject was also receiving inhaled corticosteroids.  No 
other significant medical conditions were reported in either group. 
 
AD subjects had significantly higher LSBMC and LSBA; with a similar though non-
significant trend in WBBMC, WBBA, WBBMD, WBBMD Z score, LSBMDZ, Hip 
BMC and Hip BA (Table 4).   
 
Size-adjusted bone mass 
We explored whether the increase in LSBMC was due to a concomitant increase in bone 
size in the AD group. Supporting this, we found no difference between groups in (i): 
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LSBMC, after adjusting for height, weight and LSBA (LSBMC 2.7% lower in group S: 
95% CI -8.9 to 3.6); and (ii) lumbar spine BMAD Z scores.  There were no group 
differences in WBBMC and hip BMC adjusted for height, weight and BA (WBBMC 
1.6% lower (95% CI -4.5 to 1.4) and Hip BMC 2.5% lower (-8.5 to 3.5)) in group S: nor 
in lean/height and WBBMC/lean ratios.  
 
Neonatal aluminum exposure and bone mass: non-randomised analyses 
Calculated neonatal aluminum exposure from parenteral nutrition varied with both the 
type of solution and duration of parenteral feeding. Values for the exposure of infants 
(μg/kg) by randomised group (Figure 2) showed overlap, with values in 24 infants falling 
into a common range. Mean (SD), median (25th, 75th centiles), minimum and maximum 
concentrations in the two groups were 3.0 (0.8), 28 (17,46), 4, 152 μ/kg for the AD group 
and 21.3 (7.2), 280 (91,417), 19, 840 μ/kg for group S (p<0.001 for all).  
 
The total aluminum exposure from PN as a continuous variable was not a significant 
predictor of adjusted BMC at any site, after adjusting for relevant neonatal variables 
(birthweight, gestation, days of ventilation, days of iv feeding) and follow-up variables 
(age, sex, weight, height, BA). However, to look for a 'threshold' effect, aluminum 
exposure was categorised as 'low' and 'high' using the median exposure (55mcg/kg) as a 
cut-off.  Subjects with ‘high’ exposure had significantly lower hip BMC (by 7.6% (95% 
CI 0.21 to 2.38; p=0.02). The median value was chosen as the cut-off to ensure equal 
numbers in the two groups, especially considering the relatively small sample size. 
However, exploratory analyses using other cut-offs (not shown) suggested that there was 
 9
a significant relationship between aluminium intake and later hip BMC only once the 
intake exceeded 45 mcg/kg. The largest effect size was seen using a cut-off of 65μ/kg 
(adjusted hip BMC -9.6% (-15.8 to -3.3) lower in group S). Above this level the effect 
plateaued.  This association was not present for any other skeletal site. For example, 
using the median exposure (55mcg/kg) as a cut-off, adjusted whole body BMC was 2.7% 
(-6.1 to 0.7) lower in group S and lumbar spine BMC was 3.0% (-9.8 to 3.9) lower. 
   
Current calcium intake and physical activity did not predict size-adjusted bone mass (data 
not shown). Fracture rates were not influenced by (i) randomised group or (ii) whether 
aluminum exposure was below or above the median (24% and 23% for lower versus 
higher aluminum exposure group in both comparisons).  No subject reported repeated 
fractures or unusual fragility fractures suggestive of poor bone health. 
 
Discussion 
Our study produced two principle findings suggesting that brief exposure to aluminum 
from standard PN solutions used in the neonatal period may impair long term bone 
mineralisation.  Firstly, subjects born preterm and randomised to an aluminium-depleted 
parenteral nutrition solution had significantly higher whole body BMC and BA, and 
higher lumbar spine BMC, BA and BMD during adolescence. After adjusting for current 
body and bone size, these differences between groups were no longer significant, 
suggesting that the higher bone mass reflects greater skeletal size in the AD group.  
Secondly, in non-randomised analyses relating neonatal aluminium exposure to later bone 
outcomes, we found that hip BMC was reduced in subjects with aluminium exposure 
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above the median (>55mcg/kg) than in those with lower exposure. In contrast to the 
effect on whole body and lumbar spine bone mass seen in the randomised comparison, 
the higher hip BMC associated with ‘low’ aluminium exposure was not apparently 
related to greater bone size.  These findings have potential relevance for later 
osteoporosis and fracture risk.  
 
Short-term adverse effects of aluminum on bone health have been shown in animals and 
adult humans7, but no study has previously investigated whether such effects persist 
beyond the period of exposure. Our work in other areas shows neonatal influences may 
have lasting effects on bone health indices.  Thus, we showed so-called ‘metabolic bone 
disease of prematurity’, due to early calcium and phosphorus insufficiency, is linked to 
stunting of linear growth later in childhood13.  Recently, we found an association between 
greater intakes of human milk intake during the neonatal period and higher whole body 
BMC and BA in young adults born preterm14.  These observations suggest early 
interventions may affect later skeletal size and mineralisation; and add plausibility to our 
findings here. 
 
Our findings have contemporary relevance.  In practice, despite greater recognition of 
aluminum toxicity, little progress has been made on reducing exposure. Poole3 recently 
concluded that meeting current FDA recommendations to limit aluminum exposure to 
<5mcg/kg/day is impossible in patients weighing <50kg using currently available PN 
products; and calculated aluminum exposure in infants <3kg was 30.3-59.9mcg/kg/day – 
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indeed, somewhat higher than the calculated exposure of infants receiving standard PN 
solution in our trial. 
 
The mechanism for long-term effects of aluminum on bone health is unclear. A direct 
toxic effect seems unlikely since bone tissue will have been replaced more than once by 
age 13-15 years. Possibly, aluminum exposure might “program” the responsiveness of 
bone such that, for example, subjects exposed to more aluminum form less bone for a 
given level of mechanical stimulus. This could explain the apparent site-specific effects 
of aluminum exposure.  Alternatively, aluminum might have neurotoxic effects, affecting 
central mechanisms controlling bone mass.  Indeed, bone remodelling is partly controlled 
by the central nervous system. In animals, several neuropeptides affect bone formation 
via the hypothalamus, with signal transmission to bone cells via the sympathetic nervous 
system15. Plausibly, then, the effects observed here might be another facet of early 
aluminium neurotoxicity rather than reflecting a direct effect on bone. If so, our study 
may have under-estimated the effect of aluminium exposure, since by design our protocol 
excluded subjects with known neurological impairment or with a Bayley score less than 
85. 
 
Whilst the effects of high aluminium exposure on BMC of the lumbar spine appeared 
related primarily to reduced lumbar spine bone size (bone area), effects on hip BMC were 
apparently unrelated to any corresponding stunting of hip bone growth. It is well 
recognised that interventions may have differential effects at different skeletal sites. For 
example, exercise typically affects only loaded bones16, whilst leptin has different effects 
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on the trabecular and appendicular skeleton, perhaps through differential influences on 
trabecular and cortical bone17. Such differential effects cannot be studied by DXA, used 
here, which provides no information on bone geometry or structure - likely determinants 
of bone strength and fracture risk.. Hence we suggest future explanatory studies require 
additional techniques such as hip structural analysis or pQCT. 
 
Study limitations 
The major limitation of our study relates to the inevitable cohort attrition over 15 years 
since study initiation. We could only test 33% of eligible subjects (32% of survivors); a 
follow-up rate typical of that reported in a variety of other recent long-term cohort 
studies18. We recently discussed the implications of cohort attrition for data analysis and 
interpretation, and emphasised the importance of explicitly considering effects on study 
power, bias and generalisability18. Our original planned sample size (128 subjects) would 
detect a difference of 0.5SD between groups at 80% power and 5% significance; but with 
around 60 subjects here, we had the power to detect a difference of 0.7SD and might have 
missed smaller, though biologically relevant effects. Regarding selection bias, subjects 
followed here tended to be those with higher birth-weight SD scores; nevertheless, if 
adverse effects of aluminum exposure were seen in larger infants, the effects on smaller, 
more vulnerable infants might be at least as large, if not greater. 
 
Secondly, we did not quantify all possible sources of parenteral aluminum, for instance 
from occasional albumin infusions. This would not be expected to influence the bone 
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outcome differences seen between randomised groups, but we cannot exclude an effect in 
the non-randomised analyses. 
 
The long-term clinical significance of the observed effects of early aluminum exposure 
on bone mass at 13-15 years cannot currently be quantified; albeit our subjects were only 
5-8 years from attaining peak bone mass, considered a powerful predictor of outcome.  
The estimated effect was sizeable: hip bone mass was 7.6% lower when aluminum 
exposure was above the median; and in those randomised to standard parenteral nutrition 
solutions, lumbar spine BMC was 0.7SD lower - around 14% of population variance, if 
normally distributed.  Of potential relevance here, we note that Hernandez19 suggests the 
strongest predictor of osteoporosis risk is peak bone mass, estimating a 10% increase 
would delay the onset of osteoporosis by 10 years.  
 
Conclusion 
Neonates exposed to parenteral aluminum may have reduced lumbar spine and hip bone 
mass during adolescence, potential risk factors for later osteoporosis and hip fracture. Our 
randomised trial with long-term follow-up is, to our knowledge, the only one in this area. 
Our findings must be interpreted in the context of the relatively small sample size and 
multiple comparisons performed, and our findings should be confirmed on a larger 
sample and with additional tools to investigate bone indices; yet, we recognise such 
studies require many years to undertake, and reappraisal of current practice is now 
needed.  At 18 month follow-up, before significant cohort attrition, subjects from this 
cohort exposed to higher aluminum intakes had reduced developmental scores, with an 
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estimated loss of one developmental quotient point for each day of standard parenteral 
nutrition. Aluminum has no known biological purpose, and its potential hazards when 
given unphysiologically, by the parenteral route, are well recognised in other contexts. 
Given our new findings, we suggest it would be prudent, even with existing knowledge, 
to further consider reducing aluminum in modern PN solutions. This is complex20, and 
may involve one or more of three generic approaches: (i) changing (with research and 
product filing if required) existing PN components to alternatives with lower aluminum, 
such as organic phosphorus sources; (ii) use of new methodologies for aluminum removal 
from PN products (such as calcium salts); and (iii) repackaging of PN components (such 
as mineral salts) in plastic vials to reduce contamination from glass (which may require 
new product development and testing).  Whilst these obstacles have inhibited progress, 
increasing safety concerns should now lead to re-evaluation of aluminum exposure in 
current parenteral nutrition, given to many thousands of preterm and high risk infants 
each year. 
 
 
Acknowledgements 
We thank Catherine Wilson who performed and analysed the DXA scans, Professor Tim 
Cole for helpful statistical advice, Dahlia Haroun for practical help with the study, and 
the children and parents who participated.  
 15
References 
1. Moreno A, Dominguez C, Ballabriga A. Aluminum in the neonate related to parenteral 
nutrition. Acta Paediatr 1994;83:25-29. 
2. Gura KM, Puder M. Recent developments in aluminum contamination of products 
used in parenteral nutrition. Current Op in Clin Nutr metab care 2006;9:239-246. 
3. Poole RL, Hintz SR, MacKenzie NI, Kerner JA. Aluminum exposure from pediatric 
parenteral nutrition: Meeting the new FDA regulation. J Parenteral Enteral Nutr 
2008;32:242-246. 
4. McGraw M, Bishop N, Jameson R et al. Aluminum content of milk formulae and 
intravenous fluids used in infants. Lancet 1986;jan 18th:157. 
5. Bishop NJ, Robinson MJ, Lendon M et al. Increased concentration of aluminum in the 
brain of a parenterally fed preterm infant. Arch Dis Childhood 1989;64:1316-7. 
6. Bishop NJ, Morley R, Day JP, Lucas A. Aluminum neurotoxicity in preterm infants 
receiving intravenous-feeding solutions. N Engl J Med 1997;336:1557-61. 
7. Klein G. Metabolic bone disease of total parenteral nutrition. Nutrition 1998;14:149-
152. 
8. Sedman AB, Klein GL, Russell MD et al. Evidence of aluminum loading in infants 
receiving intravenous therapy. NEJM 1985;312:1337-43. 
 9. Nelson M, Hague, Cooper C, Bunker VW. Calcium intake in the elderly: validation of 
a dietary questionnaire.  J Hum Nutr Dietetics 1988;1:115-27. 
 10. Bishop N, Braillon P, Burnham J, Cimaz R, Davies J, Fewtrell M, Hogler W, 
Kennedy K, Mäkitie O, Mughal Z, Shaw N, Vogiatzi M, Ward K, Bianchi ML. Dual- 
energy X-ray aborptiometry assessment in children and adolescents with diseases that 
 16
may affect the skeleton: the 2007 ISCD Pediatric Official Positions. J Clin   
Densitom.2008;11(1):29-42. 
11. Crabtree NJ, et al. UK Paediatric reference data (GE Lunar Prodigy). Osteoporosis Int 
2004;15(S2):S6. 
12. Cole TJ. Sympercents: symmetric percentage differences on the 100 log(e) scale 
simplify the presentation of log transformed data. Stat Med. 2000;19:3109-25. 
13. Fewtrell MS, Cole TJ, Bishop NJ, Lucas A. Neonatal factors predicting childhood 
height in preterm infants: evidence for a persisting effect of early metabolic bone disease?    
J Pediatrics 2000;137:668-673. 
14. Fewtrell MS, Williams JE, Singhal A, Murgatroyd PR, Fuller N, Lucas A. Early diet 
and peak bone mass: 20 year follow-up of a randomized trial of early diet in infants born 
preterm. Bone 2009; in press. 
15. Elefteriou F. Regulation of bone remodelling by the central and peripheral nervous 
system. Arch Biochem and Biophysics 2008;473:231-236. 
16. Fewtrell MS. Osteoporosis; is primary prevention possible? In: Primary prevention by 
Nutrition Intervention in Infancy and Childhood. Eds: Lucas A, Sampson HA. Nestle 
Nutrition Workshop Series Pediatr Program 57. Karger. 2006; 135-152. 
17. Cirmanova V, beyer M, Starka L, Zajickova K. The effect of leptin on bone – an 
evolving concept of action. Physiol Res 2008;57 suppl 1:S143-51. 
18. Fewtrell MS, Kennedy K, Singhal A, Martin RM, Ness A, Hadders-Algra M,  
Koletzko B, Lucas A. How much loss to follow-up is acceptable in long-term randomised 
trials and prospective studies? Arch Dis Child 2008;93:458-61. 
 17
19. Hernandez CJ. Theoretical analysis of the relative influences of peak BMD, age-
related bone loss and menopause on the development of osteoporosis. Osteoporosis Int 
2003;14:843. 
20. Gura KM, Puder M. Recent developments in aluminum contamination of products 
used in parenteral nutrition. Current opinion in Clin Nutr and Metab Care 2006;9:239-
246. 
 
 18
Table 1.  Composition and aluminum content of the standard and aluminum-depleted 
intravenous feeding solutions. 
 
Solution   Standard   Low aluminum 
    Volume Al content Volume Al content 
    (ml)  (μ)  (ml)  (μ) 
______________________________________________________________________ 
Vamin infant   50  1.5  50  1.5 
Intralipid 20%   15  0.1  15  0.1 
Vitalipid   1  0.3  1  0.3 
Solivito   1  <0.1  1  <0.1 
Neotrace   1.6  1.2  1.6  1.2 
Potassium acid phosphate 1.3  2.8  -  - 
Polyfusor phosphate  -  -  14.4  0.3 
Calcium gluconate  8.0  38.8  -  - 
Calcium chloride  -  -  2.1  0.5 
Dextrose,sodium, potassium 102  <0.1  102  <0.1 
Total aluminum intake 45μg/kg/day   4.0-4.5μg/kg/day 
at 180ml/kg/day 
____________________________________________________________________ 
Vamin infant contained essential amino acids without added electrolytes. Intralipid 20% was a fat emulsion 
containing 20g of fatty acids per dl. Vitalipid contained fat-soluble vitamins, and Solivito contained water-soluble 
vitamins. Neotrace was an in-house preparation containing copper and zinc only. Vamin infant, Intralipid 20%, 
Vitalipid and Solivito were manufactured by Kabi Vitrum. 
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Table 2. Neonatal data for those seen or not seen at the current follow-up (mean (SD) 
unless stated). 
    Seen at 15 years  Not seen at 15 years 
    n=59    n=168    p 
____________________________________________________________________________ 
Birthweight (g)  1270 (295)   1204 (311)   0.2 
Birthweight SD score  -0.10 (0.99)   -0.51 (1.2)   0.02* 
Gestation (weeks)  28.9 (2.0)   29.0 (2.4)   0.8 
Male (n(%))   27 (46)    91 (54)    0.3 
Singleton (n(%))  42 (71)    125 (74)   0.9 
Days in study   41 (18)    38 (23)    0.4 
Days of iv   15 (9)    14 (11)    0.5 
Days to reach   15 (9)    14 (6)    0.3 
full enteral feeds 
Days of ventilation  5 (3,8)    4 (2,9)    0.2 
median (25th,75th centiles) 
*p<0.05 
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Table 3. Neonatal data for subjects seen at follow-up according to original 
randomised group (mean(SD)) unless stated. 
     Low aluminum Standard   p 
     n=33   n=26 
_______________________________________________________________________ 
Birthweight (g)   1290 (281)  1244 (316)  0.6 
Gestation (weeks)   29.0 (1.9)  28.8 (2.1)  0.6 
Boys (n(%))    17 (52)   11 (42)   0.6 
Singleton (N(%))   21 (68)   17 (77)   0.6 
Days in trial    42 (16)   41 (20)   0.7 
Days of iv feeding    12.5 (8.8)  13.2 (9.2)  0.8 
Days to reach enteral full feeds 14 (6)   15 (6)   0.6 
Total aluminum exposure   39.1 (35.6)  280 0 (212.8)  <0.001 
from PN (μg/kg) 
Daily aluminum exposure  3.0 (0.83)  21.3 (7.2)  <0.001 
from PN (μg/kg/day) 
Received human milk (n(%))  27 (82)   16 (62)   0.14 
% of enteral intake as human milk 58 (24,99)  55 (23,99)  0.7 
median (25th/75th centile) 
Days of ventilation   5 (3,8)   5 (3,7)   0.9 
median (25th/75th centile) 
Days in >30% O2   6 (5,27)  8 (4,41)  0.4 
median (25th/75th centile) 
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Table 4. Anthropometry and bone densitometry data at follow-up according to 
original randomised group 
 
     Low-Al  Standard  p 
________________________________________________________________________ 
Age at follow-up (yrs)  15.29 (0.76)  15.15 (0.76)  0.5 
 
Pubertal stage (n (%))    
    3 10 (33)   3 (12)   0.2 
(breast/genital   4 9 (30)   10 (39) 
development)   5 10 (33)   12 (46) 
    missing 1 (3)   1 (4) 
 
Reached menarche (n(%))  16 (100)  14 (93) 
Weight (kg)    63.18 (15.84)  57.38 (14.02)  0.15 
Weight SDS    0.57 (1.29)  0.15 (1.14)  0.2 
Height (cm)    163.6 (8.3)  162.2 (7.4)  0.5 
Height SDS    -0.40 (1.03)  -0.42 (0.70)  0.9 
Head circumference (cm)  55.2 (5.2)  55.3 (1.8)  0.9 
HC SDS    -0.48 (3.7)  -0.22 (1.03)  0.7 
BMI (kg/m2)    25.6 (13.2)  21.8 (4.2)  0.2 
BMI SDS    1.07 (1.50)  0.50 (1.17)  0.1 
MUAC (cm)    26.9 (6.0)  26.6 (4.3)  0.8 
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Waist circumference (cm)  75.0 (12.9)  73.9 (11.1)  0.7 
 
Bone densitometry data 
Whole body BMC less head (g) 1909 (355)  1739 (339)  0.07 
Whole body BA less head (cm2) 1870 (225)  1769 (215)  0.09 
Whole body BMD less head (g/cm2) 1.014 (0.079)  0.976 (0.083)  0.08 
Whole body BMD Z score  0.26 (0.84)  -0.19 (0.94)  0.054 
 
Hip BMC (g)    32.4 (5.8)  29.7 (5.7)  0.08 
Hip BA (cm2)    31.1 (3.3)  29.8 (3.2)  0.1 
Hip BMD (g/cm2)   1.04 (0.094)  0.992 (0.130)  0.15 
 
Lumbar spine BMC (g)  44.9 (8.8)  39.8 (6.5)  0.02 
Lumbar spine BA (cm2)  40.5 (5.4)  37.8 (3.7)  0.03 
Lumbar spine BMD (g/cm2)  1.102 (0.119)  1.053 (0.149)  0.2 
Lumbar spine BMD Z score  -0.23 (1.20)  -0.63 (1.28)  0.2 
Lumbar spine BMAD Z score 0.046 (1.0)  -0.081 (1.22)  0.7 
 
Fat mass (kg)    18.5 (10.5)  15.5 (10.1)  0.3 
Lean mass (kg)   41.8 (9.2)  39.2 (6.9)  0.2 
Lean/height**3   9.45 (1.27)  9.14 (0.98)  0.32 
BMC-head/lean**0.7   0.20 (0.02)  0.19 (0.03)  0.1
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Figure 1.  Study plan 
  
Infants      Randomised groups 
      Standard  Low aluminum 
Total enrolled     112   115 
Died in neonatal period   14   13 
Lost to follow-up by 18 mo   8   7 
Seen at 18 mo     90   92 
 
Eligible for 15 yr follow-up   85   92 
Seen for follow-up    26   33  
Declined or failed to attend    12   10 
No reply to invitation    24   24 
Untraceable     23   25 
 
Not eligible for 15 yr follow-up   13   10 
Previous Bayley score <85 or   10   8 
neurocognitive impairment,  
or no Bayley performed  
Received no TPN    3   2 
Figure 2. Calculated aluminum exposure from parenteral nutrition during the 
neonatal period according to randomized group. Each symbol represents a single 
subject. 
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